

THE MICROBIOME, IMMUNE DEVELOPMENT, CHRONIC INFLAMMATION, AND CANCER

TAYLOR N. TIBBS^{1*}, LACEY R. LOPEZ^{1*}, and JANELLE C. ARTHUR^{1,2,3}

¹Department of Microbiology and Immunology, ²Center for Gastrointestinal Biology and Disease, and ³Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

INTRODUCTION

Our microbiota is an integral part of our mammalian selves. Indeed, all multi-cellular eukaryotic hosts across the tree of life have an essential and characteristic microbiota that influences host development and resistance to disease. Within complex organisms such as vertebrates, we harbour numerous microbial communities whose composition and function are relevant to their habitat at different body sites, such as the intestines (“gut”), skin, and oral cavity. Our gut microbiota is perhaps the best studied, most abundant, and arguably, the most influential microbiota that impacts host phenotypes. In the recent decades, the development of several scientific tools has exponentially increased our understanding of the microbiota and interactions with its human host. These include model organisms, most notably “gnotobiotic” laboratory mice that are born and raised germ-free (GF) and then colonized with individual strains or groups of microbes. Through the use of GF and gnotobiotic mice, we have been able to demonstrate causality of specific microbes and microbial groups with distinct processes of immune development and non-infectious diseases like chronic inflammation and cancer, among others. To validate the

physiologic relevance of observations made in model organisms with human disease, we can now survey the human microbiota at an unprecedented depth using culture-independent molecular methods (i.e. targeted 16S “microbiome” sequencing, metagenomics, meta-transcriptomics, and metabolomics) coupled with sophisticated bioinformatics pipelines. An important finding from population studies of the microbiome has revealed that the compositional fluctuations in an individual’s microbiome over time are less substantial than inter-individual differences at a particular stage in development. However, the developmental changes that occur during early life and over an individual’s lifespan certainly shape the composition and function of the microbiota. Indeed, the composition and functional capabilities of the microbiota shape host development. The focus of the 2018 Old Herborn University Seminar Series 32 is “Ageing and the Microbiome”. Accordingly, in this chapter we discuss the current state of knowledge regarding the influence of our mammalian microbiota on the immune system, chronic inflammation, and a prominent disease of the ageing – cancer.

*Both first authors contributed equally to this chapter

THE IMMUNE SYSTEM AND MICROBIOME IN AGEING

The immune system is our major host defence system that is educated early in life to distinguish harmful stimuli, including bacteria. It is broadly subdivided into two branches, the innate and adaptive immune systems. The innate immune response is the first line of defence towards invading pathogens. For example, this branch of the immune system is involved when host cell pattern recognition receptors are triggered by conserved pathogen specific molecules which promote an immediate and broad-spectrum protective response to pathogens. Conversely, the adaptive immune response relies on antigen presenting cells (APCs) to present bacterial products to effector T and B lymphocytes and create a pathogen-specific immunological memory and response. Through precise coordination, these systems provide host defence against foreign invaders. However, to efficiently mediate its response, the immune system must accurately distinguish between normal host-associated organisms and those that are potentially deleterious (Chaplin, 2010). Over the course of our lifetime, our immune system encounters a diverse range of stimuli in a variety of contexts, which challenges the ability of the immune system to differentiate between self and non-self (Ponnappan and Ponnappan, 2011). Alterations in this response can result in the development of a variety of diseases that include inflammatory bowel disease (IBD) and cancer (Narendra et al., 2013; Gálvez, 2014). As these immune responses are shaped over a lifetime, it indicates that age impacts the recognition of stimuli, which could transfer towards inappropriately reacting to residential host microbes. Inappropriate reactions to normal commensal bacteria may underlie a variety of pathogenic processes.

Microbial influences on immune development

Establishment of the microbiota begins from birth and continues until post-weaning (Bergström et al., 2014). During establishment, the microbiota is highly diverse and prone to fluctuations based on environmental and dietary changes (Penders et al., 2006). After 2-3 years of age, this complex community stabilizes with the majority of bacterial community members remaining unchanged throughout the lifespan of an individual (Rajilić-Stojanović et al., 2013). After stabilization, the core human microbiota mainly comprises the following phyla: *Bacteroidetes* and *Firmicutes*, with a smaller abundance of *Actinobacteria*, *Proteobacteria*, and *Verrucomicrobia* (Arumugam et al., 2011). The ageing process strongly impacts the composition of the microbiota as individuals with increased frailty, an assessment of biological age based on current health status and life expectancy, lose bacterial diversity and form a *Bacteroidetes* dominant population (Claesson et al., 2011). While not directly correlated to chronological ageing, this loss of diversity most often begins between 75-80 years of age and is a form of dysbiosis that potentiates disease development (Biagi et al., 2010). These results are a generality from a diverse population, and only consider numerical age (lifespan) rather than the individual's ageing-related health status (health span). Despite this correlation, it is important to remember that the microbiota play a largely protective role in disease development by initiating and educating the host immune system (Pickard et al., 2017).

Early observations in GF mice demonstrated that the host microbiota is essential for the maturation of the immune system (Clavel et al., 2017; Pickard et al., 2017). In the absence of

a microbiota, GF mice have several immunological defects, including reduced lymphoid cell numbers and function (Fiebigler et al., 2016). For example, GF mice have less T helper type 1 (Th1) cells compared to their conventionalized counterparts (Wu and Wu, 2012). Th1 cells promote cell-mediated immune responses and phagocyte-dependent inflammation to target intracellular pathogens (Damsker et al., 2010). Th1 responses in GF mice can be restored through host colonization with a variety of microbes, including *Listeria monocytogenes* which promotes Th1 development through macrophage production of the T-cell-stimulating factor, interleukin 12 (IL-12) (Hsieh et al., 1993). In the gut, Th1 responses are driven by intracellular bacteria like *L. monocytogenes* (Atarashi et al., 2015). Additionally, GF mice have a reduced number of T helper type 17 (Th17) cells. Th17 cells are like Th1 cells in that they are pro-inflammatory; however, they drive the production of IL-17, a cytokine which mediates defence against extracellular pathogens and auto-immune disease (Damsker et al., 2010; Wu and Wu, 2012). Colonization of GF mice with intestinally adherent pathogens, such as Clostridia-related segmented filamentous bacteria (SFB), induces the development of Th17 cells in the small intestine by driving the release of serum amyloid A from intestinal epithelial cells (IECs). The release of serum amyloid A results in the production of innate lymphoid cell group 3 activating cytokines which upregulate the Th17 response (Ivanov et al., 2009). Fine-tuning of Th1 and Th17 responses is essential for immune tolerance towards the host microbiota, as seen in the case of IBD where aberrant populations of Th1 and Th17 cells lead to enhanced pathology (Gálvez, 2014). Therefore, underdevelopment of these responses may underlie the pathogene-

sis of other diseases associated with chronic inflammation, such as cancer (Bailey et al., 2014; Vinay et al., 2015).

The absence of a microbiota impacts most, if not all, aspects of the immune system (Round and Mazmanian, 2009). However, it is not fully understood where the window of opportunity lies for correcting many of these immune deficiencies. One study examining colonic invariant natural killer T (iNKT) cell populations revealed that this opportunity for modulation likely occurs in early life (An et al., 2014). At birth, GF mice have an enriched population of colonic lamina propria iNKT cells compared to specific-pathogen-free (SPF) mice (Olszak et al., 2012). iNKT cells are pro-inflammatory and mediate cell tolerance to commensal microbes (Chandra and Kronenberg, 2015). Colonization of adult (>5 weeks of age) GF mice with a complex microbiota does not influence the number and activity of iNKT cells (An et al., 2014). However, if the colonization occurs when GF mice are neonates, the number of iNKT cells is reduced and their later activation is well-controlled (An et al., 2014). This early education of the colonic iNKT cell population is important for limiting morbidity associated with IBD (An et al., 2014). This supports the idea that exposure to specific microbes and microbial products is needed within a certain developmental time for the host to appropriately educate their target immune population and prevent disease.

The gastrointestinal tract houses one of the largest and most diverse collection of microbes in the human body (Thursby and Juge, 2017). In the intestine, a single layer of epithelial cells separates the underlying mucosal immune system from the microbiota. Due to this proximity, much work has focused upon the protective role of the microbiota on inflammatory immune

responses that can lead to intestinal inflammation or colitis. For example, GF mice colonized with a beneficial non-toxin-producing strain of *Bacteroides fragilis* exhibit a marked expansion of regulatory T-cells (Tregs) in the intestinal mucosa (Round and Mazmanian, 2010). This expansion of Tregs limits inappropriate inflammation and is important for preventing autoimmune disease through immunotolerance towards self-antigens (Round and Mazmanian, 2010; Rothstein and Camirand, 2015). This protection is mediated by *Bacteroides spp.* through the production of polysaccharide-A (PSA), a commensal microbial surface molecule presented by APCs to modulate Treg specific immune responses. Indeed, colonization with PSA + *B. fragilis* protects mice from chemically TNBS-induced and *Helicobacter hepaticus*-induced colitis (Round and Mazmanian, 2010). Furthermore, colonization of conventional mice with *Clostridium butyricum* protects against experimentally-induced colitis by promoting the expansion of immunosuppressive interleukin-10 (IL-10) secreting macrophages and mature Tregs (Hayashi et al., 2013). *B. fragilis* and *C. butyricum* belong to the most highly represented bacterial phyla within the murine and human microbiota (*Bacteroidetes* and *Firmicutes*, respectively) and mechanistically represent some of the many ways the commensal microbiota can modulate host immune responses to prevent the onset of disease (Belkaid and Harrison, 2017; Clavel et al., 2017; Pickard et al., 2017).

The immune system and ageing

The presence of a microbiota in early life is essential for immune system maturation. However, education of the immune response is a lifelong process. Alterations to the innate and adaptive immune systems which occur with in-

creased frailty are linked to a complex biological process known as immunosenescence (Fülöp et al., 2016). Specific changes associated with immunosenescence can best be understood through functional differences within the unique cell types of the innate and adaptive immune systems. For cells of the innate immune system, there are reported functional differences for every major cell type (Castelo-Branco and Soveral, 2014). However, the most distinct differences are within neutrophil and macrophage populations. Neutrophils isolated from the blood of individuals, aged 62-83, displayed reduced phagocytic capabilities and decreased production of reactive oxygen species (ROS) when infected with *Staphylococcus aureus* (Wenisch et al., 2000). These neutrophils, versus cells isolated from younger adult patients, also had impaired bactericidal activity (Wenisch et al., 2000). Neutrophils are the first line of defence towards invading pathogens. Therefore, immunosenescence related changes to this cell type suggest an age-related decline in pathogen tolerance (Chaplin, 2010). Similarly, primary macrophages isolated from aged mice (18-24 months old) have impaired phagocytosis and reduced ROS production in response to infection when compared to macrophages isolated from young mice (2-3 months old) (Davila et al., 1990; Swift et al., 2001). Additionally, macrophages from aged mice display altered antigen presentation and reduced production of pro-inflammatory cytokines (Herrero et al., 2001; Renshaw et al., 2002). Alterations in macrophage antigen presentation and cytokine release may lead to altered immune signalling between the innate and adaptive immune systems, resulting in a weakened immune response (Chaplin, 2010). Overall, age-related changes to the innate immune system strongly reduce the host's initial re-

sponse to pathogens.

While changes in the innate immune system have been noted with ageing, alterations to the adaptive immune system may be more pronounced (*Linton and Dorshkind, 2004; Castelo-Branco and Soveral, 2014*). The adaptive immune system is used for long-term protection from environmental insult and invading pathogens. Therefore, long-term education of this subsystem could have additive effects on immunosenescence. B-cells are one of the major cell types of the adaptive immune system. The population of B-cells is divided into plasma cells or memory B-cells. Plasma cells produce pathogen specific antibodies, while memory B-cells provide long-term recognition of antigens (*Eibel et al., 2014*). Peripheral blood isolated from elderly individuals (aged 86-94 years) showed a reduction in B-cell population diversity, likely due to a decrease in memory B-cells (*Gibson et al., 2009*). This decline in B-cell diversity was linked to increased frailty and may be used as a predictor for general health status (*Gibson et al., 2009*). A reduction in memory B-cells may cause an inappropriate immune response towards the microbiota, as B-cells are important for establishing the distinction between pathogenic and commensal bacteria (*Eibel et al., 2014*).

T-cells are the second major cell type of the adaptive immune system. Under normal immunological conditions, T-cells differentiate into either T Helper (Th) cells or natural killer T (NKT) cells. This differentiation is based on antigen presentation by APCs and is necessary to form a pathogen-specific immune response (*Chandra and Kronenberg, 2015*). Populations of T-cells isolated from the peripheral blood of elderly humans (aged 72-89 years) showed a reduction in the proportion of NKT-cells versus cells isolated from young patients (aged 25-

30 years) (*DelaRosa et al., 2002*). This finding was matched by a study which showed a reduction in the proportion of NKT-cells isolated from the peripheral blood of adults aged 61 years and over (*Jing et al., 2007*). Additionally, NKT-cells isolated from the liver of aged mice (aged >20 months) demonstrated a decline in cytotoxic function, and reduced cytokine release versus T-cells isolated from young mice (aged 2 months) (*Mocchegiani et al., 2004*). Under non-immunosenescence conditions, NKT-cells respond to antigenic activation by robust proliferation and directed cytotoxicity (*Chandra and Kronenberg, 2015*). Therefore, the reduced proportion of NKT-cells and cytotoxic ability in elderly organisms may exacerbate disease development by weakening the host's response to pathogens.

The host microbiota initiates immune system maturation in early life. However, to keep up with a lifelong antigenic load, the immune response must be fine-tuned and properly educated across the lifespan. Changes to the immune system that occur with age are noted within immunosenescence whereby functional differences develop within innate and adaptive immune cell populations. Despite these observations, it remains unclear how these immunological changes impact cellular crosstalk and overall immunocompetence. On top of this, how the microbiota impacts the immune system during immunosenescence remains to be elucidated. It is likely that changes to the immune system result in an inappropriate response towards commensal microbes, as indicated by diseases like IBD (*Sun et al., 2015*). Therefore, these inappropriate reactions to the native microbiota may contribute to the development of chronic inflammation and the onset of age-related diseases, such as cancer (*Tilg et al., 2018*).

MICROBIOME AND CANCER – A DISEASE OF AGEING

Cancer is considered a disease of old age. As life expectancy increases, the estimated rate of cancer is predicted to increase by 45% from 2011 to 2030 in the United States (Smith et al., 2009). It is also estimated that by 2030, individuals 65 years and older will contribute to 70% of all cancers in the United States (White et al., 2014). The risk of developing cancer increases dramatically with age as the duration of time in which an individual is exposed to carcinogens increases (Harding et al., 2012), the proliferative capacity of ageing cells decreases (Pompei et al., 2001), and immunological competence decreases (Bonafè et al., 2002). Cancer typically results from a series of genetic mutations or epigenetic modifications that develop sequentially overtime (Loeb et al., 2003). The colon, which harbours the largest and most diverse microbiota of all organs, has the highest incidence rate of all reported cancers in the 85+ population (Thakkar et al., 2014). Over the past decade, we have become increasingly aware of the roles that the microbiota play in the development of cancer and modulation of cancer therapies. We have also elucidated several mechanisms underlying the microbial influences on cancer. However, these roles are diverse and seem to influence many aspects of immune and cancer development (Fulbright et al., 2017). Microbes can contribute to the onset and progression of cancer through direct means, such as by producing genotoxins, and indirect means through the modulation of immune responses to tumours and immunotherapy (Rhee et al., 2009; Arthur et al., 2012; Kostic et al., 2013; Boleij et al., 2015; Gopalakrishnan et al., 2018). Additionally, several members of the native microbiota can alter chemotherapeutic

drugs, resulting in unpleasant side effects for the host or even rendering them clinically inert (Al-Dasooqi et al., 2011; Geller et al., 2017). It is therefore important to divulge the significance of microbial interactions on age-related diseases, such as cancer, in order to fully understand disease progression and design suitable therapies.

The ability to manipulate the microbiota using GF and gnotobiotic mice has demonstrated the importance of the microbiota on immune system development. The microbiota assist in training the immune system to recognize harmful and non-harmful stimuli, both from the environment and within the self. Here we will discuss known mechanisms by which the microbiota can influence anti-cancer chemotherapeutic activities and anti-tumour immunomodulatory responses. For example, *Clostridia spp.* are capable of suppressing the body's anti-tumour immune responses. Host-derived primary bile acids are converted into secondary bile acids by the gut microbiota, primarily members of the genus *Clostridia*, and circulated systemically throughout the body via hepatic circulation (Ridlon et al., 2006). Previous work illustrated that secondary bile acids can increase the risk of obesity-associated hepatocellular carcinoma in susceptible mice (Yoshimoto et al., 2013). Recent data suggests that antibiotic elimination of the gut microbiota in mice decreases both primary and metastatic tumours within the liver by facilitating the build-up of primary bile acids, which trigger liver-specific NKT-cell recruitment to target cancer cells (Ma et al., 2018). The profound effects bacteria illicit on cytotoxic immune cells provide key insights on how the native microbiota influence host anti-tumour responses.

Another example, *Fusobacterium nucleatum*, a Gram-negative oral commensal overrepresented in colorectal carcinoma, can promote tumorigenesis through the modulation of the innate immune system (Castellarin et al., 2012; Kostic et al., 2013). A known target is the natural killer (NK) cell, which kills compromised host cells, such as infected or cancerous cells. *F. nucleatum* inhibits the cytotoxicity of NK-cells via the Fusobacterium protein Fap2 which binds the NK-cell inhibitor receptor TIGIT (T-cell immunoglobulin and ITIM or immunoreceptor tyrosine-based inhibition motif domain) (Gur et al., 2015). In addition to targeting the immune system, it should be mentioned that *F. nucleatum* exerts pro-carcinogenic activities directly on epithelial cells through β -catenin signalling, altering cell fate (Rubinstein et al., 2013). *F. nucleatum* can also alter the efficacy of chemotherapeutic drugs by inhibiting host cell apoptotic pathways (Yu et al., 2017). *F. nucleatum* is a prime example of one species of the microbiota that exhibits a variety of different effects on the host to mediate tumorigenesis and hinder cancer therapy. In the next few sections, we will discuss a variety of known bacterial mechanisms that act upon cancer development and treatment.

Cancer immunotherapy and the microbiota

Several independent groups have recently demonstrated that some members of the microbiota play critical roles in determining patient responsiveness to cancer immunotherapy. The exact mechanisms by which individual species of bacteria exhibit these effects are not fully understood. However, current data suggest that bacterial modulation of the immune system may be one critical mode of altering host response to cancer therapy. Recent data regard-

ing anti-PD1 therapy supports this notion. Anti-PD1 treatment is a type of immune checkpoint inhibitor that enhances anti-tumour immune responses by maintaining T-cell activation via blocking the immune inhibitory receptors programmed death ligand-1 and 2 (PDL-1 and PDL-2) (Shields et al., 2017). Anti-PD1 therapy is often prescribed to patients with lung cancer and advanced melanoma. However, the efficacy of anti-PD1 immunotherapy ranges from only 19 to 43% for both cancer types (Jiang et al., 2015; Larkin et al., 2015). Several members of the microbiota are enriched in PD-1 responders, including *Bifidobacterium longum*, *Collinsella aerofaciens*, and *Enterococcus faecium* (Matson et al., 2018). *Faecalibacterium*, an abundant Gram-positive genus of commensals in the human gut (Shabbir et al., 2016), was also enriched in PD1-responders (Gopalakrishnan et al., 2018). Tumour-bearing mice that were given faecal microbiota transplants (FMTs) from PD1-responders exhibited decreased tumour burden and tumour size when receiving anti-PD1 therapy. *Faecalibacterium* promoted cytotoxic (CD8+) T-cell recruitment to tumours, which may be an important mechanism underlying the ability of this bacterial group to enhance anti-PD1 responses and reduce tumour burden (Gopalakrishnan et al., 2018). Similarly, another group demonstrated that FMTs from PD-1 responders enhanced PD-1 treatment in recipient mice, which was further augmented with oral supplementation of the commensal *Akkermansia muciniphila* (Routy et al., 2018). Antibiotic treatment reduced the efficacy of PD-1 immunotherapy in mice, consistent with clinical reports of reduced PD-1 efficacy in patients simultaneously taking antibiotics (Routy et al., 2018). These studies demonstrate that multiple species of bacteria have the capability

of altering immunotherapeutic responses in patients. Moving forward, it may be critical to consider the contributions of these microbial communities when developing anti-tumour immunotherapies.

Chemotherapy and the microbiota

Multiple members of the microbiota can differentially influence cancer chemotherapy, with some enhancing and some inhibiting the clinical effects of chemotherapeutic drugs. An important early observation was that genotoxic platinum chemotherapies, including oxaliplatin and cisplatin, were ineffective in tumour-bearing GF mice (*Iida et al., 2013*). Thus, the presence of a complex microbiota is essential for these chemotherapies (*Iida et al., 2013*). Platinum chemotherapies utilize ROS to induce cytotoxicity. The DNA damage induced by cisplatin is augmented via the production of mitochondrial ROS within cancer cells themselves (*Marullo et al., 2013*). Data also indicates that the ROS production from tumour-associated inflammatory cells are critical for the efficacy of these platinum chemotherapeutic drugs (*Iida et al., 2013*). It may be that in the absence of a native microbiota, inflammatory cells are not effectively primed to produce ROS during development, leading to shortcomings in ROS production later in life. This data highlights the influential capacity of the microbiota on the host and how in their absence the immune system may have substantial deficits in anti-tumour responses. Conversely, the microbiota can have negative effects on chemotherapeutic efficacy. Deep sequencing for microbes within pancreatic tumour biopsies revealed that 57.5% of pancreatic tumour tissues tested (65 of 113 samples) were positive for bacterial reads, with *Gammaproteobacteria* being the most abundant (51.7% of reads)

(*Geller et al., 2017*). Interestingly, 98.4% of *Gammaproteobacteria* contain genes that encode a specific isoform of the enzyme cytidine deaminase (CDDL), which has the ability to breakdown gemcitabine and confer chemotherapeutic resistance in tumour tissues (*Geller et al., 2017*). Accordingly, bacterial migration from the gastrointestinal tract into the pancreatic ducts and tumour tissue may be a significant source of drug failure in clinical pancreatic cancer cases. Gut bacteria are also responsible for re-activating chemotherapeutic drugs in the distal intestine. Irinotecan, a chemotherapeutic drug used to treat colorectal cancer (CRC), is inactivated by the liver, but reactivated into the activate drug by *Clostridia spp.* through β -glucuronidases in the gut (*Stringer et al., 2009*). This re-activation contributes to the typical unpleasant gastrointestinal side effects of irinotecan therapy, including mucositis and diarrhoea (*Stringer et al., 2009; Al-Dasooqi et al., 2011*). This evidence illustrates the profound impact the native microbiota can have on the response to cancer therapies. Therefore, future treatment plans should account for the influence of these patient-specific microbial factors to ensure successful outcomes.

Direct effects of the microbiota on tumourigenesis

Specific members of the microbiota have the capacity to directly contribute to tumourigenesis (*Schwabe and Jobin, 2013; Fulbright et al., 2017*). Commensal *Enterobacteriaceae*, including several strains of *Escherichia coli*, are capable of inducing DNA damage in mammalian cells by producing a genotoxin termed colibactin (*Cuevas-Ramos et al., 2010; Arthur et al., 2012*). The bacterial polyketide synthase (*pks*) pathogenicity island encoding colibactin is up-regulated in CRC models and

the presence of these gene products promotes tumourigenesis by inducing double-stranded DNA breaks (Nougayrede et al., 2006; Arthur et al., 2014; Tomkovich et al., 2017). Colibactin can also induce premature cellular senescence in cells that initially survive the DNA damage (Secher et al., 2013; Cougnoux et al., 2014). Furthermore, the *pks* pathogenicity island is over-represented in the microbiota of CRC and IBD patients (Arthur et al., 2012; Buc et al., 2013; Prorok-Hamon et al., 2014). This suggests that bacterial genotoxins likely contribute substantially in the development of human cancer and chronic inflammatory diseases.

Bacteria also have the capacity to induce a pro-tumourigenic environment through chronic inflammation. Enterotoxigenic *B. fragilis*, a member of the most abundantly represented genus in the gut, produces its own flavour of toxin called *B. fragilis*-derived toxin (BFT) (Wu et al., 2002). BFT is a zinc-dependent metalloprotease that can induce colitis and promote tumourigenesis through the generation of ROS and subsequent initiation of DNA damage in epithelial cells (Goodwin et al., 2011). Enterotoxigenic *B. fragilis* robustly activates Th17 immune responses, which involves the inflammatory cytokine interleukin-17 (IL-17), and may lower host anti-tumour immune responses, encouraging unhindered tumour growth (Wu et al., 2009; Geis et al., 2015). Enterotoxigenic *B. fragilis* is overrepresented in patients with CRC when compared to healthy individuals (Boleij et al., 2015) and exacerbates tumourigenesis in susceptible mice (Wu et al. 2009). Interestingly, the tumourigenic effects of *pks*+ *E. coli* and enterotoxigenic *B. fragilis* act synergistically *in vivo* to quicken tumour onset and increase mortality in susceptible mice beyond the capability

that either species has individually (Dejea et al., 2018). Given that the native microbial community is quite complex, the cumulative effects of microbial products on the host may significantly contribute to the onset of cancer.

One of the earliest identified microbial suspects of inflammation-mediated cancer development is *Helicobacter pylori*. While widely considered a pathogen, *H. pylori* is estimated to be present in the gastrointestinal tract of over half of the human population worldwide and a major risk factor for gastric adenocarcinoma (Arthur and Jobin, 2011; Hooi et al., 2017). It is estimated that *H. pylori* infection increases the attributable risk of gastric cancer by 73% (Herrera and Parsonnet, 2009). Chronic *H. pylori* infection results in inflammation and tissue damage by the bacterial virulence factor CagA (cytotoxin-associated gene A), which initiates the development of the hallmark precursory lesions of gastric cancer, including intestinal metaplasia and dysplasia (Diaz et al., 2018). It remains unclear why *H. pylori* infection only progresses to malignancy in a subset of infected individuals; however, it is postulated that host immune responses and the genetics of both host and bacteria contribute to neoplastic development (Polk and Peek, 2010). The evidence presented here illustrates the diverse microbial mechanisms that contribute to tumourigenesis, whether that be by directly targeting the DNA for damage through a toxin or by providing an augmented environment for unrestricted cellular proliferation.

In summary, the mechanisms by which the native microbiota influences cancer development and therapy are numerous and diverse. As more data surfaces, it will be imperative to synthesize and apply knowledge on microbial contributions towards cancer

development and treatment. By doing so, we can more effectively assess cancer risk and ultimately design more potent therapies.

LITERATURE

- Al-Dasooqi, N., Bowen, J.M., Gibson, R.J., Logan, R.M., Stringer, A.M., and Keefe, D.M.: Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. *Int. J. Exp. Pathol.* 92, 357-365 (2011).
- An, D., Oh, S.F., Olszak, T., Neves, J.F., Avci, F., Erturk-Hasdemir, D., Lu, X., Zeissig, S., Blumberg, R.S., and Kasper, D.L.: Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. *Cell* 156, 123-133 (2014).
- Arthur, J.C. and Jobin, C.: The struggle within: microbial influences on colorectal cancer. *Inflamm. Bowel Dis.* 17, 396-409 (2011).
- Arthur, J.C., Perez-chañona, E., Mühlbauer, M., Tomkovich, S., Uronis, J.M., Fan, T., Campbell, B.J., Abujamel, T., Dogan, B., Rogers, A.B., Rhodes, J.M., Stintzi, A., Simpson, K.W., Hansen, J.J., Keku, T.O., Fodor, A.A., and Jobin, C.: Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science* 338, 120-123 (2012).
- Arthur, J.C., Gharaibeh, R.Z., Mühlbauer, M., Perez-Chañona, E., Uronis, J.M., McCafferty, J., Fodor, A.A., and Jobin, C.: Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. *Nat. Commun.* 5, 2724 (2014).
- Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D.R., Fernandes, G.R., Tap, J., Bruls, T., Batto, J.M., Bertalan, M., Borruel, N., Casellas, F., Fernandez, L., Gautier, L., Hansen, T., Hattori, M., Hayashi, T., Kleerebezem, M., Kurokawa, K., Leclerc, M., Levenez, F., Manichanh, C., Nielsen, H.B., Nielsen, T., Pons, N., Poulain, J., Qin, J., Sicheritz-Ponten, T., Tims, S., Torrents, D., Ugarte, E., Zoetendal, E.G., Wang, J., Guarner, F., Pedersen, O., de Vos, W.M., Brunak, S., Doré, J.; MetaHIT Consortium, Antolín, M., Artiguenave, F., Blottiere, H.M., Almeida, M., Brechot, C., Cara, C., Chervaux, C., Cultrone, A., Delorme, C., Denariáz, G., Dervyn, R., Foerstner, K.U., Friss, C., van de Guchte, M., Guedon, E., Haimet, F., Huber, W., van Hylckama-Vlieg, J., Jamet, A., Juste, C., Kaci, G., Knol, J., Lakhdari, O., Layec, S., Le Roux, K., Maguin, E., Mérieux, A., Melo Minardi, R., M'Trini, C., Muller, J., Oozeer, R., Parkhill, J., Renault, P., Rescigno, M., Sanchez, N., Sunagawa, S., Torrejon, A., Turner, K., Vandemeulebrouck, G., Varela, E., Winogradsky, Y., Zeller, G., Weissenbach, J., Ehrlich, S.D., and Bork, P.: Enterotypes of the human gut microbiome. *Nature* 473, 174-180 (2011).
- Atarashi, K., Tanoue, T., Ando, M., Kamada, N., Nagano, Y., Narushima, S., Suda, W., Imaoka, A., Setoyama, H., Nagamori, T., Ishikawa, E., Shima, T., Hara, T., Kado, S., Jinohara, T., Ohno, H., Kondo, T., Toyooka, K., Watanabe, E., Yokoyama, S., Tokoro, S., Mori, H., Noguchi, Y., Morita, H., Ivanov, I.I., Sugiyama, T., Nuñez, G., Camp, J.G., Hattori, M., Umesaki, Y., and Honda, K.: Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells. *Cell* 163, 367-380 (2015).
- Bailey, S.R., Nelson, M.H., Himes, R.A., Li, Z., Mehrotra, S., and Paulos, C.M.: Th17 cells in cancer: the ultimate identity crisis. *Front. Immunol.* 5, 1-13 (2014).
- Belkaid, Y. and Harrison, O.J.: Homeostatic immunity and the microbiota. *Immunity* 46, 562-576 (2017).
- Bergström, A., Skov, T.H., Bahl, M.I., Roager, H.M., Christensen, L.B., Ejlerskov, K.T., Mølgaard, C., Michaelsen, K.F., and Licht, T.R.: Establishment of intestinal microbiota during early life: a longitudinal, explorative

- study of a large cohort of Danish infants. *Appl. Environ. Microbiol.* 80, 2889-2900 (2014).
- Biagi, E., Nylund, L., Candela, M., Ostan, R., Bucci, L., Pini, E., Nikkila, J., Monti, D., Satokari, R., Franceschi, C., Brigidi, P., and De Vos, W.: Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. *PLoS One* 5, e10667 (2010).
- Boleij, A., Hechenbleikner, E.M., Goodwin, A.C., Badani, R., Stein, E.M., Lazarev, M.G., Ellis, B., Carroll, K.C., Albesiano, E., Wick, E.C., Platz, E.A., Pardoll, D.M., and Sears, C.L.: The *Bacteroides fragilis* toxin gene is prevalent in the colon mucosa of colorectal cancer patients. *Clin. Infect. Dis.* 60, 208-215 (2015).
- Bonafè, M., Barbi, C., Storci, G., Salvioli, S., Capri, M., Olivieri, F., Valensin, S., Monti, D., Gonos, E.S., De Benedictis, G., and Franceschi, C.: What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians. *Exp. Gerontol.* 37, 1263-1271 (2002).
- Buc, E., Dubois, D., Sauvanet, P., Raisch, J., Delmas, J., Darfeuille-Michaud, A., Pezet, D., and Bonnet, R.: High prevalence of mucosa-associated *E. coli* producing cyclomodulin and genotoxin in colon cancer. *PLoS One* 8, e56964 (2013).
- Castellarin, M., Warren, R.L., Freeman, D.J., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R.A., and Holt, R.A.: *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *Genome Res.* 22, 299-306 (2012).
- Castelo-Branco, C. and Soveral, I.: The immune system and aging: a review. *Gynecol. Endocrinol.* 30, 16-22 (2014).
- Chandra, S. and Kronenberg, M.: Activation and Function of iNKT and MAIT Cells. *Adv. Immunol.* 127, 145-201 (2015).
- Chaplin, D.D.: Overview of the Immune Response David. *J. Allergy Clin. Immunol.* 125, Suppl. 2, S3-23 (2010).
- Claesson, M.J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery, E., Marchesi, J.R., Falush, D., Dinan, T., Fitzgerald, G., Stanton, C., van Sinderen, D., O'Connor, M., Harnedy, N., O'Connor, K., Henry, C., O'Mahony, D., Fitzgerald, A.P., Shanahan, F., Twomey, C., Hill, C., Ross, R.P., and O'Toole, P.W.: Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc. Natl. Acad. Sci. USA* 108, 4586-4591 (2011).
- Clavel, T., Gomes-Neto, J.C., Lagkouvardos, I., and Ramer-Tait, A.E.: Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes. *Immunol. Rev.* 279, 8-22 (2017).
- Cougnoux, A., Dalmasso, G., Martinez, R., Buc, E., Delmas, J., Gibold, L., Sauvanet, P., Darcha, C., Déchelotte, P., Bonnet, M., Pezet, D., Wodrich, H., Darfeuille-Michaud, A., and Bonnet, R.: Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. *Gut* 63, 1932-1942 (2014).
- Cuevas-Ramos, G., Petit, C.R., Marcq, I., Boury, M., Oswald, E., and Nougayrède, J.-P.: *Escherichia coli* induces DNA damage in vivo and triggers genomic instability in mammalian cells. *Proc. Natl. Acad. Sci. USA* 107, 11537-11542 (2010).
- Damsker, J.M., Hansen, A.M., and Caspi, R.R.: Th1 and Th17 cells: adversaries and collaborators. *Ann. NY Acad. Sci.* 1183, 211-221 (2010).
- Davila, D.R., Edwards III, C.K., Arkins, S., Simon, J., and Kelley, K.W.: Interferon-gamma-induced priming for secretion of superoxide anion and tumor necrosis factor-alpha declines in macrophages from aged rats. *FASEB J.* 4, 2906-2911 (1990).
- Dejea, C.M., Fathi, P., Craig, J.M., Boleij, A., Geis, A.L., Wu, X., DeStefano Shields, C.E., Hechenbleikner, E.M., Huso, D.L., Anders, R.A., Giardiello, F.M., Wick, E.C., Wang, H., Wu, S., Pardoll, D.M., Housseau, F., and Sears, C.L.: Patients with familial adenomatous polyposis harbor

- colonic biofilms containing tumorigenic bacteria. *Science* 359, 592-597 (2018).
- DelaRosa, O., Tarazona, R., Casado, J.G., Alonso, C., Ostos, B., Pena, J., and Solana, R.: $V\alpha 24+$ NKT cells are decreased in elderly humans. *Exp. Gerontol.* 37, 213-217 (2002).
- Díaz, P., Valenzuela Valderrama, M., Bravo, J., and Quest, A.F.G.: *Helicobacter pylori* and Gastric Cancer: Adaptive Cellular Mechanisms Involved in Disease Progression. *Front. Microbiol.* 9, 1-10 (2018).
- Eibel, H., Kraus, H., Sic, H., Kienzler, A.-K., and Rizzi, M.: B cell Biology: An Overview. *Curr. Allergy Asthma Rep.* 14, 1-10 (2014).
- Fiebiger, U., Bereswill, S., and Heimesaat, M.M.: Dissecting the interplay between intestinal microbiota and host immunity in health and disease: Lessons learned from germfree and gnotobiotic animal models. *Eur. J. Microbiol. Immunol. (Bp.)* 6, 253-271 (2016).
- Fulbright, L.E., Ellermann, M., and Arthur, J.C.: The microbiome and the hallmarks of cancer. *PLoS Pathog.* 13, e1006480 (2017).
- Fülöp, T., Dupuis, G., Witkowski, J.M., and Larbi, A.: The Role of Immunosenescence in the Development of Age-Related Diseases. *Rev. Invest. Clin.* 68, 84-91 (2016).
- Gálvez, J.: Role of Th17 Cells in the Pathogenesis of Human IBD. *ISRN Inflamm.* 2014, 928461 (2014).
- Geis, A.L., Fan, H., Wu, X., Wu, S., Huso, D.L., Wolfe, J.L., Sears, C.L., Pardoll, D.M., and Housseau, F.: Regulatory T Cell Response to Enterotoxigenic *Bacteroides fragilis* Colonization Triggers IL17-Dependent Colon Carcinogenesis. *Cancer Discov.* 5, 1098-1109 (2015).
- Geller, L.T., Barzily-Rokni, M., Danino, T., Jonas, O.H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z.A., Shee, K., Thaiss, C.A., Reuben, A., Livny, J., Avraham, R., Frederick, D.T., Ligorio, M., Chatman, K., Johnston, S.E., Mosher, C.M., Brandis, A., Fuks, G., Gurbatri, C., Gopalakrishnan, V., Kim, M., Hurd, M.W., Katz, M., Fleming, J., Maitra, A., Smith, D.A., Skalak, M., Bu, J., Michaud, M., Trauger, S.A., Barshack, I., Golan, T., Sandbank, J., Flaherty, K.T., Mandinova, A., Garrett, W.S., Thayer, S.P., Ferrone, C.R., Huttenhower, C., Bhatia, S.N., Gevers, D., Wargo, J.A., Golub, T.R., and Straussman, R.: Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. *Science* 357, 1156-1160 (2017).
- Gibson, K.L., Wu, Y.-C., Barnett, Y., Duggan, O., Vaughan, R., Kondeatis, E., Nilsson, B.O., Wikby, A., Kipling, D., and Dunn-Walters, D.K.: B-cell diversity decreases in old age and is correlated with poor health status. *Aging Cell* 8, 18-25 (2009).
- Goodwin, A.C., Shields, C.E.D., Wu, S., Huso, D.L., Wu, X., Murray-Stewart, T.R., Hacker-Prietz, A., Rabizadeh, S., Woster, P.M., Sears, C.L., and Casero Jr., R.A.: Polyamine catabolism contributes to enterotoxigenic *Bacteroides fragilis*-induced colon tumorigenesis. *Proc. Natl. Acad. Sci. USA* 108, 15354-15359 (2011).
- Gopalakrishnan, V., Spencer, C.N., Nezi, L., Reuben, A., Andrews, M.C., Karpinet, T.V., Prieto, P.A., Vicente, D., Hoffman, K., Wei, S.C., Cogdill, A.P., Zhao, L., Hudgens, C.W., Hutchinson, D.S., Manzo, T., Petaccia de Macedo, M., Cotechini, T., Kumar, T., Chen, W.S., Reddy, S.M., Szczepaniak Sloane, R., Galloway-Pena, J., Jiang, H., Chen, P.L., Shpall, E.J., Rezvani, K., Alousi, A.M., Chemaly, R.F., Shelburne, S., Vence, L.M., Okhuysen, P.C., Jensen, V.B., Swennes, A.G., McAllister, F., Marcelo Riquelme Sanchez, E., Zhang, Y., Le Chatelier, E., Zitvogel, L., Pons, N., Austin-Breneman, J.L., Haydu, L.E., Burton, E.M., Gardner, J.M., Sirmans, E., Hu, J., Lazar, A.J., Tsujikawa, T., Diab, A., Tawbi, H., Glitza, I.C., Hwu, W.J., Patel, S.P., Woodman, S.E., Amaria, R.N., Davies, M.A., Gershenwald, J.E., Hwu, P., Lee, J.E., Zhang, J., Coussens, L.M., Cooper, Z.A., Futreal, P.A., Daniel, C.R., Ajami, N.J., Petrosino, J.F., Tetzlaff, M.T., Sharma, P., Allison, J.P., Jenq, R.R., and

- Wargo, J.A.: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science* 359, 97-103 (2018).
- Gur, C., Ibrahim, Y., Isaacson, B., Yamin, R., Abed, J., Gamliel, M., Enk, J., Bar-On, Y., Stanietzky-Kaynan, N., Copenhagen-Glazer, S., Shussman, N., Almogy, G., Cuapio, A., Hofer, E., Mevorach, D., Tabib, A., Ortenberg, R., Markel, G., Miklić, K., Jonjic, S., Brennan, C.A., Garrett, W.S., Bachrach, G., and Mandelboim, O.: Binding of the Fap2 protein of *Fusobacterium nucleatum* to human inhibitory receptor TIGIT protects tumors from immune cell attack. *Immunity* 42, 344-355 (2015).
- Harding, C., Pompei, F., and Wilson, R.: Peak and decline in cancer incidence, mortality, and prevalence at old ages. *Cancer* 118, 1371-1386 (2012).
- Hayashi, A., Sato, T., Kamada, N., Mikami, Y., Matsuoka, K., Hisamatsu, T., Hibi, T., Roers, A., Yagita, H., Ohteki, T., Yoshimura, A., and Kanai, T.: A single strain of *Clostridium butyricum* induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. *Cell Host Microbe* 13, 711-722 (2013).
- Herrera, V. and Parsonnet, J.: *Helicobacter pylori* and gastric adenocarcinoma. *Clin. Microbiol. Infect.* 15, 971-976 (2009).
- Herrero, C., Marqués, L., Lloberas, J., and Celada, A.: IFN- γ -dependent transcription of MHC class II IA is impaired in macrophages from aged mice. *J. Clin. Invest.* 107, 485-493 (2001).
- Hooi, J.K.Y., Lai, W.Y., Ng, W.K., Suen, M.M.Y., Underwood, F.E., Tanyingoh, D., Malfertheiner, P., Graham, D.Y., Wong, V.W.S., Wu, J.C.Y., Chan, F.K.L., Sung, J.J.Y., Kaplan, G.G., and Ng, S.C.: Global Prevalence of *Helicobacter pylori* Infection: Systematic Review and Meta-Analysis. *Gastroenterology* 153, 420-429 (2017).
- Hsieh, C., Macatonia, S.E., Tripp, C.S., Wolf, S.F., O'Garra, A., and Murphy, K.M.: Development of Th1 CD4⁺ T Cells Through IL-12 Produced by Listeria-Induced Macrophages. *Science* 260, 547-549 (1993).
- Iida, N., Dzutsev, A., Stewart, C.A., Smith, L., Bouladoux, N., Weingarten, R.A., Molina, D.A., Salcedo, R., Back, T., Cramer, S., Dai, R.M., Kiu, H., Cardone, M., Naik, S., Patri, A.K., Wang, E., Marincola, F.M., Frank, K.M., Belkaid, Y., Trinchieri, G., and Goldszmid, R.S.: Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. *Science* 342, 967-971 (2013).
- Ivanov, I.I., Atarashi, K., Manel, N., Brodie, E.L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K.C., Santee, C.A., Lynch, S.V., Tanoue, T., Imaoka, A., Itoh, K., Takeda, K., Umesaki, Y., Honda, K., and Littman, D.R.: Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell* 139, 485-498 (2009).
- Jiang, Y., Chen, B., Duan, C., Sun, B., Yang, J., and Yang, S.: Multigene editing in the *Escherichia coli* genome via the CRISPR-Cas9 system. *Appl. Environm. Microbiol.* 81, 2506-2514 (2015).
- Jing, Y., Gravenstein, S., Chaganty, R.N., Chen, N., Lyerly, K.H., Joyce, S., and Deng, Y.: Aging is associated with a rapid decline in frequency, alterations in subset composition, and enhanced Th2 response in CD1d-restricted NKT cells from human peripheral blood. *Exp. Gerontol.* 42, 719-732 (2007).
- Kostic, A.D., Chun, E., Robertson, L., Glickman, J.N., Gallini, C.A., Michaud, M., Clancy, T.E., Chung, D.C., Lochhead, P., Hold, G.L., El-Omar, E.M., Brenner, D., Fuchs, C.S., Meyerson, M., and Garrett, W.S.: *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor immune microenvironment. *Cell Host Microbe* 14, 207-215 (2013).
- Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P.F., Hill, A., Wagstaff, J., Carlino, M.S., Haanen, J.B., Maio, M., Marquez-Rodas, I., McArthur, G.A., Ascierto, P.A., Long, G.V., Callahan, M.K., Postow, M.A., Grossmann, K., Sznol,

- M., Dreno, B., Bastholt, L., Yang, A., Rollin, L.M., Horak, C., Hodi, F.S., and Wolchok, J.D.: Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *New Engl. J. Med.* 373, 23-34 (2015).
- Linton, P.J. and Dorshkind, K.: Age-related changes in lymphocyte development and function. *Nat. Immunol.* 5, 133-139 (2004).
- Loeb, L.A., Loeb, K.R., and Anderson, J.P.: Multiple mutations and cancer. *Proc. Natl. Acad. Sci. USA* 100, 776-781 (2003).
- Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J.A., Fako, V., Ritz, T., Longerich, T., Theriot, C.M., McCulloch, J.A., Roy, S., Yuan, W., Thovarai, V., Sen, S.K., Ruchirawat, M., Korangy, F., Wang, X.W., Trinchieri, G., and Greten, T.F.: Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. *Science* 360, eaan5931 (2018).
- Marullo, R., Werner, E., Degtyareva, N., Moore, B., Altavilla, G., Ramalingam, S. S., and Doetsch, P.W.: Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. *PLoS One* 8, 1-15 (2013).
- Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J.J., and Gajewski, T.F.: The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science* 359, 104-108 (2018).
- Mocchegiani, E., Giacconi, R., Cipriano, C., Gasparini, N., Bernardini, G., Malavolta, M., Menegazzi, M., Cavalieri, E., Muzzioli, M., Ciampa, A.R., and Suzuki, H.: The variations during the circadian cycle of liver CD1d-unrestricted NK1.1+TCR gamma/delta+ cells lead to successful ageing. Role of metallothionein/IL-6/gp130/PARP-1 interplay in very old mice. *Exp. Gerontol.* 39, 775-788 (2004).
- Narendra, B.L., Reddy, K.E., Shantikumar, S., and Ramakrishna, S.: Immune system: A double-edged sword in cancer. *Inflamm. Res.* 62, 823-834 (2013).
- Nougayrede, J.P., Homburg, S., Taieb, F., Boury, M., Brzuszkiewicz, E., Gottschalk, G., Buchrieser, C., Hacker, J., Dobrindt, U., and Oswald, E.: *Escherichia coli* Induces DNA Double-Strand Breaks in Eukaryotic Cells. *Science* 313, 848-852 (2006).
- Olszak, T., An, D., Zeissig, S., Vera, M. P., Richter, J., Franke, A., Glickman, J.N., Siebert, R., Baron, R.M., Kasper, D.L., and Blumberg, R.S.: Microbial exposure during early life has persistent effects on natural killer T cell function. *Science* 336, 489-493 (2012).
- Penders, J., Thijs, C., Vink, C., Stelma, F.F., Snijders, B., Kummeling, I., van den Brandt, P.A., and Stobberingh, E.E.: Factors influencing the composition of the intestinal microbiota in early infancy. *Pediatrics* 118, 511-521 (2006).
- Pickard, J.M., Zeng, M.Y., Caruso, R., and Núñez, G.: Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. *Immunol. Rev.* 279, 70-89 (2017).
- Polk, D.B. and Peek, R.M.: *Helicobacter pylori*: Gastric cancer and beyond. *Nat. Rev. Cancer* 10, 403-414 (2010).
- Pompei, F., Polkanov, M., and Wilson, R.: Age distribution of cancer in mice: the incidence turnover at old age. *Toxicol. Ind. Health* 17, 7-16 (2001).
- Ponnappan, S. and Ponnappan, U.: Aging and Immune Function: Molecular Mechanisms to Interventions. *Antioxid. Redox Signal.* 14, 1551-1585 (2011).
- Prorok-Hamon, M., Friswell, M.K., Alswied, A., Roberts, C.L., Song, F., Flanagan, P.K., Knight, P., Codling, C., Marchesi, J.R., Winstanley, C., Hall, N., Rhodes, J.M., and Campbell, B.J.: Colonic mucosa-associated diffusely adherent afaC+ *Escherichia coli* expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. *Gut* 63, 761-770 (2014).
- Rajilić-Stojanović, M., Heilig, H.G.H.J., Tims, S., Zoetendal, E.G., and de Vos, W.M.: Long-term monitoring of the human intestinal microbiota composition. *Environ. Microbiol.* 15, 1146-1159 (2013).

- Renshaw, M., Rockwell, J., Engleman, C., Gewirtz, A., Katz, J., and Sambhara, S.: Cutting edge: impaired Toll-like receptor expression and function in aging. *J. Immunol.* 169, 4697-4701 (2002).
- Rhee, K.J., Wu, S., Wu, X., Huso, D.L., Karim, B., Franco, A.A., Rabizadeh, S., Golub, J.E., Mathews, L.E., Shin, J., Sartor, R.B., Golenbock, D., Hamad, A.R., Gan, C.M., Housseau, F., and Sears, C.L.: Induction of persistent colitis by a human commensal, enterotoxigenic *Bacteroides fragilis*, in wild-type C57BL/6 mice. *Infect. Immun.* 77, 1708-1718 (2009).
- Ridlon, J.M., Kang, D.J., and Hylemon, P.B.: Bile salt biotransformations by human intestinal bacteria. *J. Lipid Res.* 47, 241-259 (2006).
- Rothstein, D.M. and Camirand, G.: New insights into the mechanisms of Treg function. *Curr. Opin. Organ Transplant.* 20, 376-384 (2015).
- Round, J.L. and Mazmanian, S.K.: The gut microbiota shapes intestinal immune responses during health and disease. *Nat. Rev. Immunol.* 9, 313-323 (2009).
- Round, J.L. and Mazmanian, S.K.: Inducible Foxp3⁺ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *Proc. Natl. Acad. Sci. USA* 107, 12204-12209 (2010).
- Routy, B., Le Chatelier, E., Derosa, L., Duong, C.P.M., Alou, M.T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M.P., Fidelle, M., Flament, C., Poirier-Colame, V., Opolon, P., Klein, C., Iribarren, K., Mondragón, L., Jacquelot, N., Qu, B., Ferrere, G., Clémenson, C., Mezquita, L., Masip, J.R., Naltet, C., Brosseau, S., Kaderbhai, C., Richard, C., Rizvi, H., Levenez, F., Galleron, N., Quinquis, B., Pons, N., Ryffel, B., Minard-Colin, V., Gonin, P., Soria, J.C., Deutsch, E., Lorient, Y., Ghiringhelli, F., Zalcman, G., Goldwasser, F., Escudier, B., Hellmann, M.D., Eggermont, A., Raoult, D., Albiges, L., Kroemer, G., and Zitvogel, L.: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science* 359, 91-97 (2018).
- Rubinstein, R.M., Wang, X., Liu, W., Hao, Y., Cai, G., and Han, Y.W.: *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/ β -catenin signaling via its FadA adhesin. *Cell Host Microbe* 14, 195-206 (2013).
- Schwabe, R.F. and Jobin, C.: The microbiome and cancer. *Nat. Rev. Cancer* 13, 800-812 (2013).
- Secher, T., Samba-Louaka, A., Oswald, E., and Nougayrède, J.P.: *Escherichia coli* producing colibactin triggers premature and transmissible senescence in mammalian cells. *PLoS One* 8, e77157 (2013).
- Shabbir, M.A.B., Hao, H., Shabbir, M.Z., Wu, Q., Sattar, A., and Yuan, Z.: Bacteria vs. Bacteriophages: Parallel Evolution of Immune Arsenal. *Front. Microbiol.* 7, 1292 (2016).
- Shields, B.D., Mahmoud, F., Taylor, E.M., Byrum, S.D., Sengupta, D., Koss, B., Baldini, G., Ransom, S., Cline, K., Mackintosh, S.G., Edmondson, R.D., Shalin, S. and Tackett, A.J.: Indicators of responsiveness to immune checkpoint inhibitors. *Sci. Rep.* 7, 807 (2017).
- Smith, B.D., Smith, G.L., Hurria, A., Hortobagyi, G.N., and Buchholz, T.A.: Future of cancer incidence in the United States: burdens upon an aging, changing nation. *J. Clin. Oncol.* 27, 2758-2765 (2009).
- Stringer, A.M., Gibson, R.J., Bowen, J.M., Logan, R.M., Ashton, K., Yeoh, A.S. J., Al-Dasooqi, N., and Keefe, D.M.K.: Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. *Int. J. Exp. Pathol.* 90, 489-499 (2009).
- Sun, M., He, C., Cong, Y., and Liu, Z.: Regulatory immune cells in regulation of intestinal inflammatory response to microbiota. *Mucosal Immunol.* 8, 969-978 (2015).
- Swift, M.E., Burns, A.L., Gray, K.L., and DiPietro, L.A.: Age-related alterations in the inflammatory response to dermal injury. *J. Invest. Dermatol.* 117, 1027-1035 (2001).

- Thakkar, J.P., McCarthy, B.J., and Villano, J.L.: Age-specific cancer incidence rates increase through the oldest age groups. *Am. J. Medical Sci.* 348, 65-70 (2014).
- Thursby, E. and Juge, N.: Introduction to the human gut microbiota. *Biochem. J.* 474, 1823-1836 (2017).
- Tilg, H., Adolph, T.E., Gerner, R.R., and Moschen, A.R.: The Intestinal Microbiota in Colorectal Cancer. *Cancer Cell* 33, 1-11 (2018).
- Tomkovich, S., Yang, Y., Winglee, K., Gauthier, J., Mühlbauer, M., Sun, X., Mohamadzadeh, M., Liu, X., Martin, P., Wang, G.P., Oswald, E., Fodor, A.A., and Jobin, C.: Locoregional effects of microbiota in a preclinical model of colon carcinogenesis. *Cancer Res.* 77, 2620-2632 (2017).
- Vinay, D.S., Ryan, E.P., Pawelec, G., Talib, W.H., Stagg, J., Elkord, E., Lichtor, T., Decker, W.K., Whelan, R.L., Kumara, H.M.C.S., Signori, E., Honoki, K., Georgakilas, A.G., Amin, A., Helferich, W.G., Boosani, C.S., Guha, G., Ciriolo, M.R., Chen, S., Mohammed, S.I., Azmi, A.S., Keith, W.N., Bilsland, A., Bhakta, D., Halicka, D., Fujii, H., Aquilano, K., Ashraf, S.S., Nowsheen, S., Yang, X., Choi, B.K., and Kwon, B.S.: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Semin. Cancer Biol.* 35 Suppl., S185-S198 (2015).
- Wenisch, C., Patruta, S., Daxböck, F., Krause, R., and Hörl, W.: Effect of age on human neutrophil function. *J. Leukoc. Biol.* 67, 40-45 (2000).
- White, M.C., Holman, D.M., Boehm, J.E., Peipins, L.A., Grossman, M., and Henley, S.J.: Age and cancer risk: A potentially modifiable relationship. *Am. J. Prev. Med.* 46, Suppl. 1, S7-S15 (2014).
- Wu, H.J. and Wu, E.: The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes* 3, 4-14 (2012).
- Wu, S., Dreyfus, L.A., Tzianabos, A.O., Hayashi, C., and Sears, C.L.: Diversity of the metalloprotease toxin produced by enterotoxigenic *Bacteroides fragilis*. *Infect. Immun.* 70, 2463-2471 (2002).
- Wu, S., Rhee, K., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H., Huso, D.L., Brancati, F.L., Wick, E., McAllister, F., Housseau, F., Pardoll, D.M., and Sears, C.L.: A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nat. Med.* 15, 1016-1022 (2009).
- Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., Honda, K., Ishikawa, Y., Hara, E., and Ohtani, N.: Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. *Nature* 499, 97-101 (2013).
- Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., Chen, Y., Chen, H., Hong, J., Zou, W., and Fang, J.Y.: *Fusobacterium nucleatum* Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. *Cell* 170, 548-563 (2017).